Tech companies are focusing on AI products over research, say industry experts, who are sounding the alarm about safety.

Read about the move to scale use of AI across all FDA centers by the end of June and learn more about future plans to expand ...

There could be an upside to incorporating AI for the FDA. Using AI to assist in final drug reviews would "represent a chance ...

AI-powered tools are enhancing precision, efficiency, and decision-making in biopharmaceutical development. Recently, Jared ...

The FDA  plans to launch generative AI across all of its centers by June 30. The agency has also appointed its first chief AI ...

The FDA is rolling out an aggressive plan to make generative AI a linchpin in its decision-making, part of a bid to get faster and leaner in evaluating drugs, foods, medical devices and diagnostic ...

May 12, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Artificial Intelligence (AI) is becoming more essential in ... drive sustained performance as both entities plan to interact with the ...

The success of AI in healthcare is influenced more by human factors and organizational readiness than by the technology ...

Experts have cautioned against adopting the technology too quickly for clinical purposes. The first meeting of FDA’s Digital ...

The US Food and Drug Administration (FDA) has set an "aggressive" timeline to implement generative artificial intelligence ...

Donald Trump has promised to create a pro-AI environment, but even tech companies are frustrated by federal cuts that hamper regulatory processes. Paul Webster reports.

The Food and Drug Administration on Thursday announced an aggressive agency-wide Artificial intelligence adoption timeline ...